All posts by: Michael Zand

About Michael Zand

Gene therapy temporarily reverses diabetes in mice – FierceBiotech

Continue reading

2018-01-04 NEWS

FierceBiotech

Gene therapy temporarily reverses diabetes in mice
FierceBiotech
The team used an adeno-associated viral (AAV) vector—the same technology that’s at the heart of Spark’s gene therapy—to deliver two proteins, Pdx1 and MafA, into the pancreas. These proteins “reprogrammed” alpha cells into insulin-producing cells
Could Gene Therapy One Day Cure Diabetes?Gizmodo

all 4 news articles »

Continue reading

2018-01-04 NEWS

Gizmodo

Could Gene Therapy One Day Cure Diabetes?
Gizmodo
If we use gene therapy to get the body to make new insulin-producing cells in the body, logically it should attack those cells too.” But that’s not what happened. Using what’s known as an adeno-associated virus, they deliver two proteins, Pdx1 and MafA
Gene therapy temporarily reverses diabetes in miceFierceBiotech
Gene therapy restores normal blood glucose levels in mice with type 1 diabetesEurekAlert (press release)

all 4 news articles »

Continue reading

2018-01-04 NEWS

Efficacy and safety of chimeric antigen receptor Tcell (CAR-T) therapy in patients with haematological and solid …
UroToday
Patients with relapsed or refractory malignancies have a poor prognosis. Immunotherapy with chimeric antigen receptor T (CART) cells redirects a patient’s immune cells against the tumour antigen. CART cell therapy has demonstrated promise in treating

Continue reading

2018-01-04 NEWS

Live Science

Can Gene Editing Save the World’s Chocolate?
Live Science
Fungi and viruses are poised to doom chocolate, which is why scientists are racing to save cacao — the tree that sprouts the colorful, football-size pods containing beans used to make chocolate — with the gene-editing tool known as CRISPR-Cas9

and more »

Continue reading

2018-01-04 NEWS

nwitimes.com

Here’s What Pushed Crispr Therapeutics AG Up 23.6% in December
nwitimes.com
Shares of Crispr Therapeutics AG (NASDAQ: CRSP), a biotech start-up named after the promising new gene-editing technology it’s focused on, bounded 23.6% higher in December, according to data from S&P Global Market Intelligence. A new collaboration deal
CRISPR Therapeutics Announces Proposed Public Offering of …GlobeNewswire (press release)
A Comparison of Top Movers: Overstock.com, Inc. (OSTK), CRISPR Therapeutics AG (CRSP)StockNewsGazette
Head-To-Head Contrast: Crispr Therapeutics (CRSP) vs. Incyte (INCY)Dispatch Tribunal
The Lincolnian Online –The Ledger Gazette
all 31 news articles »
Continue reading

2018-01-04 NEWS

CNA Finance (press release)

Cellect Announces Stem Cell Triumph
Nasdaq
(RTTNews.com) – The shares of Cellect Biotechnology Ltd. ( APOP ) surged in the pre-market as it unveiled the stem cell technology breakthrough with hundred percent acceptance. Thursday, the company said its ApoGraft Stem Cell transplant has zero
Cellect Bio’s ApoGraft stem cells completely accepted by first blood cancer patients in Phase 1/2 study; shares up Seeking Alpha
Cellect (APOP) Says First Group of Patients in Clinical Trial With its ApoGraft Stem Cell Transplant Follow up StreetInsider.com
Cellect Biotechnology (APOP) Stock: Gaining On Stem Cell BreakthroughCNA Finance (press release)
ForexTV.com
all 11 news articles »